Aditx Therapeutics, Inc. is a pre-clinical stage, life sciences company. The Company is focused on developing technologies on improving the health of the immune system through immune reprogramming and monitoring. The Company’s immune reprogramming technology is at the pre-clinical stage and is designed to retrain the immune system to induce tolerance. The Company’s immune monitoring technology is designed to provide a personalized profile of the immune system. The Company is developing nucleic acid-based technology, Apoptotic DNA Immunotherapy (ADi) that mimics the way human body naturally induces tolerance to its tissues. The Company is developing Aditxt Immune Monitor (AiM), which provides a personalized comprehensive profile of the immune system.